Drug intelligence / Profile preview

Klebsiella pneumoniae phage P1524

Development stage
Preclinical
Lead developer
Peking University Third Hospital
01

Overview

Klebsiella pneumoniae phage P1524 is a novel lytic bacteriophage belonging to the *Przondovirus* genus, isolated from hospital sewage. It exhibits broad-spectrum lytic activity against high-risk, multidrug-resistant, and hypervirulent clones of *Klebsiella pneumoniae* (including ST11, ST14, and ST65 sequence types). The phage combats *K. pneumoniae* infections through a receptor-mediated evolutionary trade-off, where resistance to the phage is driven by a mutation in the host's *wcaJ* gene, leading to capsule loss, impaired biofilm formation, and reduced in vivo virulence. Additionally, phage P1524 encodes several antibacterial effectors, including Orf4, Orf15, and Orf23. Orf4 and Orf23 downregulate key enzymes of the host's 2,3-butanediol fermentation pathway (such as AldB_1, AlsS, and BudC), causing metabolic reprogramming and inhibiting bacterial growth, while Orf23 suppresses biofilm formation. The phage's HHI protein also directly binds to the host's H-NS protein to inhibit bacterial growth [1]. It is being investigated for the treatment of *Klebsiella pneumoniae* infections.

Other names
Bacteriophage P1524Klebsiella phage P1524Przondovirus phage P1524phage P1524
02

Targets

DNABII (DNABII family protein)

Beyond the preview

Go deeper on Klebsiella pneumoniae phage P1524.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Klebsiella pneumoniae phage P1524.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call